Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology..
In March 2020, the United Kingdom Primary Immunodeficiency Network (UKPIN) established a registry of cases to collate the outcomes of individuals with PID and SID following SARS-CoV-2 infection and treatment. A total of 310 cases of SARS-CoV-2 infection in individuals with PID or SID have now been reported in the UK. The overall mortality within the cohort was 17.7% (n = 55/310). Individuals with CVID demonstrated an infection fatality rate (IFR) of 18.3% (n = 17/93), individuals with PID receiving IgRT had an IFR of 16.3% (n = 26/159) and individuals with SID, an IFR of 27.2% (n = 25/92). Individuals with PID and SID had higher inpatient mortality and died at a younger age than the general population. Increasing age, low pre-SARS-CoV-2 infection lymphocyte count and the presence of common co-morbidities increased the risk of mortality in PID. Access to specific COVID-19 treatments in this cohort was limited: only 22.9% (n = 33/144) of patients admitted to the hospital received dexamethasone, remdesivir, an anti-SARS-CoV-2 antibody-based therapeutic (e.g. REGN-COV2 or convalescent plasma) or tocilizumab as a monotherapy or in combination. Dexamethasone, remdesivir, and anti-SARS-CoV-2 antibody-based therapeutics appeared efficacious in PID and SID. Compared to the general population, individuals with PID or SID are at high risk of mortality following SARS-CoV-2 infection. Increasing age, low baseline lymphocyte count, and the presence of co-morbidities are additional risk factors for poor outcome in this cohort.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:209 |
|---|---|
| Enthalten in: |
Clinical and experimental immunology - 209(2022), 3 vom: 29. Sept., Seite 247-258 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shields, Adrian M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.12.2022 Date Revised 29.03.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cei/uxac008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341633178 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341633178 | ||
| 003 | DE-627 | ||
| 005 | 20231226012229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cei/uxac008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1138.xml |
| 035 | |a (DE-627)NLM341633178 | ||
| 035 | |a (NLM)35641155 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shields, Adrian M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2022 | ||
| 500 | |a Date Revised 29.03.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. | ||
| 520 | |a In March 2020, the United Kingdom Primary Immunodeficiency Network (UKPIN) established a registry of cases to collate the outcomes of individuals with PID and SID following SARS-CoV-2 infection and treatment. A total of 310 cases of SARS-CoV-2 infection in individuals with PID or SID have now been reported in the UK. The overall mortality within the cohort was 17.7% (n = 55/310). Individuals with CVID demonstrated an infection fatality rate (IFR) of 18.3% (n = 17/93), individuals with PID receiving IgRT had an IFR of 16.3% (n = 26/159) and individuals with SID, an IFR of 27.2% (n = 25/92). Individuals with PID and SID had higher inpatient mortality and died at a younger age than the general population. Increasing age, low pre-SARS-CoV-2 infection lymphocyte count and the presence of common co-morbidities increased the risk of mortality in PID. Access to specific COVID-19 treatments in this cohort was limited: only 22.9% (n = 33/144) of patients admitted to the hospital received dexamethasone, remdesivir, an anti-SARS-CoV-2 antibody-based therapeutic (e.g. REGN-COV2 or convalescent plasma) or tocilizumab as a monotherapy or in combination. Dexamethasone, remdesivir, and anti-SARS-CoV-2 antibody-based therapeutics appeared efficacious in PID and SID. Compared to the general population, individuals with PID or SID are at high risk of mortality following SARS-CoV-2 infection. Increasing age, low baseline lymphocyte count, and the presence of co-morbidities are additional risk factors for poor outcome in this cohort | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a hypogammaglobulinemia | |
| 650 | 4 | |a inborn errors of immunity | |
| 650 | 4 | |a lymphopenia | |
| 650 | 4 | |a primary immunodeficiencies | |
| 650 | 4 | |a secondary immunodeficiencies | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a casirivimab and imdevimab drug combination |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 700 | 1 | |a Anantharachagan, Ariharan |e verfasserin |4 aut | |
| 700 | 1 | |a Arumugakani, Gururaj |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Bahal, Sameer |e verfasserin |4 aut | |
| 700 | 1 | |a Baxendale, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Bermingham, William |e verfasserin |4 aut | |
| 700 | 1 | |a Bhole, Malini |e verfasserin |4 aut | |
| 700 | 1 | |a Boules, Evon |e verfasserin |4 aut | |
| 700 | 1 | |a Bright, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Chopra, Charu |e verfasserin |4 aut | |
| 700 | 1 | |a Cliffe, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Cleave, Betsy |e verfasserin |4 aut | |
| 700 | 1 | |a Dempster, John |e verfasserin |4 aut | |
| 700 | 1 | |a Devlin, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Dhalla, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Diwakar, Lavanya |e verfasserin |4 aut | |
| 700 | 1 | |a Drewe, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Duncan, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Dziadzio, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Elcombe, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Elkhalifa, Shuayb |e verfasserin |4 aut | |
| 700 | 1 | |a Gennery, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Ghanta, Harichandrana |e verfasserin |4 aut | |
| 700 | 1 | |a Goddard, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Grigoriadou, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Hackett, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Hayman, Grant |e verfasserin |4 aut | |
| 700 | 1 | |a Herriot, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Herwadkar, Archana |e verfasserin |4 aut | |
| 700 | 1 | |a Huissoon, Aarnoud |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Rashmi |e verfasserin |4 aut | |
| 700 | 1 | |a Jolles, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Sujoy |e verfasserin |4 aut | |
| 700 | 1 | |a Laffan, James |e verfasserin |4 aut | |
| 700 | 1 | |a Lane, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Leeman, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Lowe, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Mahabir, Shanti |e verfasserin |4 aut | |
| 700 | 1 | |a Lochlainn, Dylan James Mac |e verfasserin |4 aut | |
| 700 | 1 | |a McDermott, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Misbah, Siraj |e verfasserin |4 aut | |
| 700 | 1 | |a Moghaddas, Fiona |e verfasserin |4 aut | |
| 700 | 1 | |a Morsi, Hadeil |e verfasserin |4 aut | |
| 700 | 1 | |a Murng, Sai |e verfasserin |4 aut | |
| 700 | 1 | |a Noorani, Sadia |e verfasserin |4 aut | |
| 700 | 1 | |a O'Brien, Rachael |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Smita |e verfasserin |4 aut | |
| 700 | 1 | |a Price, Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Tasneem |e verfasserin |4 aut | |
| 700 | 1 | |a Seneviratne, Suranjith |e verfasserin |4 aut | |
| 700 | 1 | |a Shrimpton, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Stroud, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Moira |e verfasserin |4 aut | |
| 700 | 1 | |a Townsend, Katie |e verfasserin |4 aut | |
| 700 | 1 | |a Vaitla, Prashantha |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Nisha |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Burns, Siobhan O |e verfasserin |4 aut | |
| 700 | 1 | |a Savic, Sinisa |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Alex G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental immunology |d 1966 |g 209(2022), 3 vom: 29. Sept., Seite 247-258 |w (DE-627)NLM00001527X |x 1365-2249 |7 nnns |
| 773 | 1 | 8 | |g volume:209 |g year:2022 |g number:3 |g day:29 |g month:09 |g pages:247-258 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cei/uxac008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 209 |j 2022 |e 3 |b 29 |c 09 |h 247-258 | ||